Forecast of the development trend of biomedical industry in 2020

[pharmaceutical network industry trends] at the end of 2019, some international biomedical industry forums reached a consensus: from the perspective of the development trend of the world's biomedical industry, it is currently at the beginning stage of large-scale industrialization of biomedical technology, and it is expected to enter a rapid development period in 2020, and gradually become the leading industry of the world economy Now that it has officially entered 2020, how will the biomedical industry develop? Next, I have three predictions to share with you Forecast of the development trend of biomedical industry in 2020 Biomedical technology mainly refers to macromolecular therapy produced by living cells After more than 40 years of development, biomedical technology has become increasingly diversified, and a more complex new drug development platform has been formed, ranging from new applications based on monoclonal antibodies, to nucleic acid (RNA) therapy, to gene therapy, etc At the same time, biopharmaceutics is also one of the sub industries with rapid development in the pharmaceutical industry in recent years The global market size is expected to rise from US $2020 billion in 2016 to US $326 billion in 2022, with an annual compound growth rate of 3% In addition, statistics show that in 2016, 7 of the top 10 drugs in global sales were bio drugs, 6 of which were monoclonal antibodies Therefore, it is predicted that by 2025, biological drugs will account for 57 out of 100 good drugs sold in the world Such a huge market space will undoubtedly attract the attention of many Chinese and foreign pharmaceutical companies At present, many countries regard biomedical industry as a strategic industry with priority in the 21st century For example, the United States has been continuously increasing investment in Biotechnology R & D and industrialization through the implementation of "biotechnology industry incentive policy" In the Sixth Framework of EU science and technology development, 45% of research and development funds are spent on biotechnology and related fields
In addition, China has repeatedly issued strong policies in recent years, focusing on improving the innovation ability and industrialization level of biomedicine, providing fertile soil for independent innovation, encouraging the development of innovation industry in multiple dimensions, speeding up the process of registration and listing, realizing the localization of related fields, and cultivating a batch of products with core independent competitiveness at the same time, and continuously improving the domestic innovation and research and development ability Power M & A and acquisition of generic pharmaceutical companies at present, the total value of the top 20 international biopharmaceutical companies is about $2.84 trillion, the total revenue in 2018 is $641 billion, and the expected growth rate in 2019 is 5% - 6%, which means that they can repay the total debt of $474 billion in less than two years As a result, although there have been several M & A events in the past year, they still have enough capital to spend on the acquisition plans of medium-sized Biopharmaceutical Enterprises with more than $10 billion According to the data, the amount of M & A among Biopharmaceutical Enterprises has reached a record high in 2019, among which three major M & A cases were Bristol Myers Squibb's acquisition of celgene, abbvie's acquisition of Allergan and Amgen's acquisition of celgene's product otezla, contributing a total of US $150 billion, among which Bristol Myers Squibb's acquisition of celgene reached a record with us $74 billion In 2020, this trend of M & A and acquisition may continue After all, new drug research and development takes a long time, with a large amount of investment, and needs to face more risks during the period Through M & A, drug research and development can be greatly accelerated Subdivisions will usher in rapid development Biopharmaceutics refer to preparations made of biotechnology using microorganisms, cells, animal or human tissues or body fluids as starting materials for the prevention, treatment and diagnosis of human diseases The development direction of biomedicine includes monoclonal antibody, protein medicine, gene and nucleic acid medicine and many other fields For example, as a new subdivision of biological drugs, antibody drugs have been developing rapidly in recent years According to Frost & Sullivan report, the market size of monoclonal antibody in China has increased from 3.5 billion yuan in 2012 to 9.1 billion yuan in 2016, with a compound annual growth rate of 26.8% It is estimated that from 2016 to 2021, it will continue to grow at a compound annual growth rate of 25.0%, reaching a market scale of 27.6 billion yuan in 2021 In the future, with the continuous development of antibody technology, a variety of monoclonal antibody derivatives will continue to emerge, including antibody drug conjugates, small molecule antibodies, bispecific antibodies and so on And those effective subdivision varieties will also usher in rapid development.